IMRT及3D-CRT对早期NSCLC患者的治疗效果和对肿瘤标记物及免疫功能的影响

doi:10.3969/j.issn.1671-7171.2018.11.009

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To analyze the effect of stereotactic body radiotherapy [SBRT: intensity-modulated radiation therapy (IMRT) and 3-D conformal radiotherapy (3D-CRT)] in patients with early non-small cell lung cancer (NSCLC) and its influence on tumor markers and immune function. 【Methods】A total of 66 patients with early NSCLC in our hospital were selected from Oct. 2014 to Feb. 2018 and were randomly divided into group A (n=33) and group B (n=33). Group A was treated with IMRT and group B was treated with 3D-CRT. The therapeutic effects of the two groups were compared. Also, effects on serum carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153), carcinoembryonic antigen (CEA) and T lymphocyte subsets CD3⁺, CD4⁺, CD4⁺/CD8⁺ index levels were compared. 【Results】 The total effective rate of group A (78.79%) was significantly higher than that of group B (78.79% vs 54.55%, χ²=4.364,P<0.05). After treatment, the serum levels of CA125, CA153 and CEA in the two groups were significantly lower than those before treatment (P<0.05),and those levels in group A were significantly lower than group B (P<0.05); After treatment, the serum levels of CD3⁺, CD4⁺, CD4⁺/CD8⁺ in the two groups were significantly lower than before treatment, and those levels in group B were significantly lower than group A (P<0.05). 【Conclusion】SBRT has good therapeutic effect on patients with early NSCLC. The effect of IMRT is better than that of 3D-CRT, and it can reduce the immune function of the body.

Received: 27 September 2018

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2018.11.009 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2018/V35/I11/2107

[1] 王晨. 非小细胞癌临床治疗进展[J].吉林医学,2014,35(16):3574-3575.
[2] 王惠. 全胸腔镜与开胸手术治疗早期非小细胞肺癌的疗效对比研究[J].临床医药文献电子杂志,2015,2(15):3012-3013.
[3] 曾昭冲. 肝癌立体定向放射治疗的临床效果[J].中国医学前沿杂志(电子版),2014,6(05):17-22.
[4] 刘惠珠,孙彦秋,赵艳海. 鼻咽癌调强放疗和三维适形放疗对患者生命质量的影响比较[J].临床和实验医学杂志,2015,14(14):1170-1173.
[5] 姚晓军,刘伦旭. 肺癌的流行病学及治疗现状[J].现代肿瘤医学,2014,22(08):1982-1986.
[6] 胡坚,包飞潮. 早期非小细胞肺癌外科治疗新进展[J].中国肺癌杂志,2016,19(06):399-402.
[7] 张晓峰. 非小细胞肺癌三维适形放疗疗效及其影响预后因素分析[J].现代医院,2016,16(11):1564-1566+1569.
[8] 张敏,戈伟,陈明,等. 三维适形放疗联合化疗同步治疗非小细胞肺癌晚期局部复发的近期疗效[J].实用癌症杂志,2016,31(02):242-245.
[9] 胜照杰,孙静. 三维适形调强放疗与三维适形放疗同步化疗对Ⅲ期非小细胞肺癌的疗效比较[J].实用癌症杂志,2016,31(07):1133-1136.
[10] 颜桂明,陈国付,张飞燕. 肿瘤精确放疗技术进展[J].医学理论与实践,2015,28(02):164-166.
[11] 刘凌湘,张超,邹国荣. 乳腺癌改良根治术后逆向与混合调强放疗剂量学比较[J].中国医学物理学杂志,2015,32(05):742-746.
[12] 董百强,陈明.立体定向放疗在非小细胞肺癌治疗中的应用[J].中华放射医学与防护杂志,2016,36(10):732-735.
[13] 张雁,王志群. 肿瘤标志物对肺癌患者的诊断及预后预测的价值研究[J].实用癌症杂志,2015,30(09):1281-1283.
[14] 石耿利. 联合检测血清CEA、CA153及CA125在诊断肺癌中的诊断价值[J].中国实用医药,2015,10(12):71-72.
[15] 郭健,高志斌,贺少枫,陈平. 肿瘤标志物与晚期肺癌立体定向放疗疗效的相关性[J].临床肺科杂志,2012,17(11):2048-2050.
[16] 杨燕光,王金云,张珏,等. 局部晚期非小细胞肺癌调强放疗与三维适形放疗的剂量学及临床疗效分析[J].中国肿瘤,2014,23(10):873-877.
[17] Bergsma DP, Salama JK, Singh DP,et al.The evolving role of radiotherapy in treatment of oligometastatic NSCLC.[J].Expert Review of Anticancer Therapy,2015, 15(12):1459-1471.
[18] 梁洪享,钟竑,黄燕,丁罡. 非小细胞肺癌肿瘤干细胞标记物的研究进展[J].现代肿瘤医学,2013,21(07):1659-1661.